Skip to main content
SpringerLink
Log in

Nuclear Imaging of Movement Disorders

  • Chapter
  • First Online:
Diseases of the Brain, Head and Neck, Spine 2016-2019

  • 2045 Accesses

Abstract

Movement disorders belong to the most common neurologic illnesses. In typical cases diagnoses are accurately established by clinical means. In early and monosymptomatic stages, however, clinical diagnoses remain uncertain and may benefit from molecular imaging techniques picking up specific metabolic patterns or changes in neurotransmitter systems. Most established for this purpose are the assessment of the metabolic pattern of fluorodeoxyglucose (FDG) and changes in dopaminergic neurotransmission. These techniques generally allow to separate Parkinson’s disease (PD) from other neurodegenerative parkinsonian syndromes (PS), to characterize dementia with Lewy bodies (DLB), and to rule out diseases which may mimic neurodegenerative PS such as symptomatic parkinsonism and various tremor syndromes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Hughes AJ, Daniel SE, Lees AJ (1993) The clinical features of Parkinson’s disease in 100 histologically proven cases. Adv Neurol 60:595–599

    CAS  PubMed  Google Scholar 

  3. Catafau AM, Tolosa E (2004) Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 19:1175–1182

    Article  PubMed  Google Scholar 

  4. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ (2002) The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125:861–870

    Article  PubMed  Google Scholar 

  5. Meara J, Bhowmick BK, Hobson P (1999) Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing 28:99–102

    Article  CAS  PubMed  Google Scholar 

  6. Eckert T, Barnes A, Dhawan V et al (2005) FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 26:912–921

    Article  PubMed  Google Scholar 

  7. Zhao P, Zhang B, Gao S (2011) 18F-FDG PET study on the idiopathic Parkinson’s disease from several parkinsonian-plus syndromes. Parkinsonism Relat Disord 18(Suppl 1):S60–S62

    Google Scholar 

  8. Varrone A, Halldin C (2012) New developments of dopaminergic imaging in Parkinson’s disease. Q J Nucl Med Mol Imaging 56:68–82

    CAS  PubMed  Google Scholar 

  9. Seibyl J, Russell D, Jennings D, Marek K (2012) The molecular basis of dopaminergic brain imaging in Parkinson’s disease. Q J Nucl Med Mol Imaging 56:4–16

    CAS  PubMed  Google Scholar 

  10. Cochrane CJ, Ebmeier KP (2013) Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis. Neurology 80:857–864

    Article  PubMed  PubMed Central  Google Scholar 

  11. Meijer FJ, Bloem BR, Mahlknecht P, Seppi K, Goraj B (2013) Update on diffusion MRI in Parkinson’s disease and atypical parkinsonism. J Neurol Sci 332:21–29

    Article  PubMed  Google Scholar 

  12. Barthel H, Schroeter ML, Hoffmann K-T, Sabri O (2015) PET/MR in dementia and other neurodegenerative diseases. Semin Nucl Med 45:224–233

    Article  PubMed  Google Scholar 

  13. Booij J, Tissingh G, Winogrodzka A, van Royen EA (1999) Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 26:171–182

    Article  CAS  PubMed  Google Scholar 

  14. Dagher A (2001) Functional imaging in Parkinson’s disease. Semin Neurol 21:23–32

    Article  CAS  PubMed  Google Scholar 

  15. Huang C, Ravdin LD, Nirenberg MJ et al (2013) Neuroimaging markers of motor and nonmotor features of Parkinson’s disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Dement Geriatr Cogn Disord 35:183–196

    Article  PubMed  Google Scholar 

  16. Borghammer P, Hansen SB, Eggers C et al (2012) Glucose metabolism in small subcortical structures in Parkinson’s disease. Acta Neurol Scand 125:303–310

    Article  PubMed  Google Scholar 

  17. Tatsch K (2010) Extrapyramidal syndromes: PET and SPECT. Neuroimaging Clin N Am 20:57–68

    Article  PubMed  Google Scholar 

  18. Bruck A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO (2009) A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson’s disease shows nonlinear progression in the putamen. Mov Disord 24:1009–1015

    Article  PubMed  Google Scholar 

  19. Hsiao IT, Weng YH, Hsieh CJ et al (2014) Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. JAMA Neurol 71:758–766

    Article  PubMed  Google Scholar 

  20. Tatsch K (2016) Movement disorders. In: von Schulthess GK (ed) Molecular anatomic imaging PET/CT, PET/MR and SPECT/CT. Wolters Kluwer, Philadelphia, pp 210–217

    Google Scholar 

  21. la Fougere C, Popperl G, Levin J et al (2011) The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes. J Nucl Med 51:581–587

    Article  Google Scholar 

  22. Pirker W, Asenbaum S, Bencsits G et al (2000) [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 15:1158–1167

    Article  CAS  PubMed  Google Scholar 

  23. Klaffke S, Kuhn AA, Plotkin M et al (2006) Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration. Mov Disord 21:1724–1727

    Article  PubMed  Google Scholar 

  24. Walker Z, Possin KL, Boeve BF, Aarsland D (2015) Lewy body dementias. Lancet 386:1683–1697

    Article  PubMed  Google Scholar 

  25. Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB (2012) Diagnostic accuracy of I-123 FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord 18:225–229

    Article  PubMed  Google Scholar 

  26. Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P (2010) Clinical features and 123I-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson’s disease. Eur J Nucl Med Mol Imaging 37:556–564

    Article  PubMed  Google Scholar 

  27. Gaig C, Marti MJ, Tolosa E et al (2006) 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism. Mov Disord 21:1994–1998

    Article  PubMed  Google Scholar 

  28. Zijlmans J, Evans A, Fontes F et al (2007) [123I] FP-CIT spect study in vascular parkinsonism and Parkinson’s disease. Mov Disord 22:1278–1285

    Article  PubMed  Google Scholar 

  29. Contrafatto D, Mostile G, Nicoletti A et al (2012) [(123) I]FP-CIT-SPECT asymmetry index to differentiate Parkinson’s disease from vascular parkinsonism. Acta Neurol Scand 126:12–16

    Article  CAS  PubMed  Google Scholar 

  30. Jeon BS, Jeong JM, Park SS et al (1998) Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 43:792–800

    Article  CAS  PubMed  Google Scholar 

  31. Benamer TS, Patterson J, Grosset DG et al (2000) [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503–510

    Article  CAS  PubMed  Google Scholar 

  32. Trocello JM, Zanotti-Fregonara P, Roze E et al (2008) Dopaminergic deficit is not the rule in orthostatic tremor. Mov Disord 23:1733–1738

    Article  PubMed  Google Scholar 

  33. Coria F, Gimenez-Garcia M, Samaranch L, Mora FJ, Sampol-Bas C, Pastor P (2012) Nigrostriatal dopaminergic function in subjects with isolated action tremor. Parkinsonism Relat Disord 18:49–53

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Municipal Hospital Karlsruhe Inc., Moltkestr. 90, Karlsruhe, 76133, Germany

    Klaus Tatsch

Authors
  1. Klaus Tatsch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Tatsch .

Editor information

Editors and Affiliations

  1. UniversitätsSpital Zürich, Zürich, Switzerland

    Jürg Hodler

  2. Zürich, Switzerland

    Rahel A. Kubik-Huch

  3. Klinik/Poliklinik Nuklearmedizin, Zürich, Switzerland

    Gustav K. von Schulthess

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Tatsch, K. (2016). Nuclear Imaging of Movement Disorders. In: Hodler, J., Kubik-Huch, R., von Schulthess, G. (eds) Diseases of the Brain, Head and Neck, Spine 2016-2019. Springer, Cham. https://doi.org/10.1007/978-3-319-30081-8_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30081-8_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30080-1

  • Online ISBN: 978-3-319-30081-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation